Recent Quotes (30 days)

You have no recent quotes
chg | %

Silence Therapeutics plc  

(Public, LON:SLN)   Watch this stock  
Find more results forSLN
-4.50 (-2.07%)
Aug 28 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 213.00 - 223.80
52 week 185.00 - 388.75
Open 215.25
Vol / Avg. 9,324.00/69,157.00
Mkt cap 112.57M*
P/E     -
Div/yield     -
EPS -0.20*
Shares 52.00M
Beta     -
Inst. own     -
Nov 24, 2014
Silence Therapeutics PLC Capital Markets Day (Estimated) Add to calendar
Sep 16, 2014
Half Year 2014 Silence Therapeutics PLC Earnings Release - 8:00am BST - Add to calendar
Jun 27, 2014
Silence Therapeutics PLC Annual Shareholders Meeting

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -7363.16% -7694.02%
Operating margin -7396.05% -7753.85%
EBITD margin - -7500.00%
Return on average assets -35.61% -38.82%
Return on average equity -37.18% -41.21%
Employees 38 -
CDP Score - -


1 Lyric Square/Hammersmith
United Kingdom - Map
+44-20-37009711 (Phone)
+44-7-957318494 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Silence Therapeutics plc (Silence Therapeutics) is engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company´┐Żs product, Atu027, is in a phase Ib/2a clinical trial. RNAi platform is built around the AtuRNAi technology and based on stabilization technology, and specific small interfering (siRNA) molecules. A delivery platform using molecules, such as AtuFECT to target a range of organs in the field with: AtuPLEX (for endothelial cells of the vascular system); DBTC (for hepatocytes and hepathic vascular system), and DACC (for vascular endothelial cells of the lung).

Officers and directors

Ali Mortazavi Chief Executive Officer, Director
Tim C. A. Freeborn Chief Financial Officer, Finance Director, Secretary, Director
Age: 53
Jia Huey Cheng Chief Operating Officer, Director
Age: 37
Michael Khan Ph.D. Chief Medical Officer, Director
Simon J. Sturge Non-Executive Chairman of the Board
Age: 55
Stephen B. Parker Independent Non-Executive Director
Age: 55
Alastair James Riddell Independent Non-Executive Director
Age: 64